StockData
InflaRx N.V. logo

InflaRx N.V. (IFRX) stock

IFRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 20, 2026Score 5/30
$1.04−0.05 (-4.59%)

Close on Nov 20, 2026Market cap $75.18MP/E –Yield –

InflaRx gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

For fiscal 2025 it was -€7.24M. The highest annual figure on record is -€469.17K in fiscal 2023.

Annual gross profit

PeriodPeriod endValueChange
FY2025Dec 31, 2025-€7.24M–
FY2024Dec 31, 2024-€3.15M–
FY2023Dec 31, 2023-€469.17K–
FY2018Dec 31, 2018-€37.82M–
FY2017Dec 31, 2017-€19.55M–
FY2016Dec 31, 2016-€7.12M–

Quarterly gross profit

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2025Jun 30, 2025-€2.36M–
Q2 FY2024Jun 30, 2024-€341.80K–
Q2 FY2019Jun 30, 2019-€16.15M–
Q2 FY2018Jun 30, 2018-€8.19M–

More InflaRx figures

See a number that looks wrong?